Last reviewed · How we verify
AQ280 Tablet for Oral Suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AQ280 Tablet for Oral Suspension (AQ280 Tablet for Oral Suspension) — AQILION AB.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AQ280 Tablet for Oral Suspension TARGET | AQ280 Tablet for Oral Suspension | AQILION AB | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AQ280 Tablet for Oral Suspension CI watch — RSS
- AQ280 Tablet for Oral Suspension CI watch — Atom
- AQ280 Tablet for Oral Suspension CI watch — JSON
- AQ280 Tablet for Oral Suspension alone — RSS
Cite this brief
Drug Landscape (2026). AQ280 Tablet for Oral Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/aq280-tablet-for-oral-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab